Recruiting

MMR Vaccine

Sponsor:

Children's Mercy Hospital Kansas City

Code:

NCT07195032

Conditions

Heart Transplant Infection Prevention

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Interventions

Commercial measles, mumps, and rubella (MMR) vaccine

Study Details

Brief summary:

The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.

Conditions

Heart Transplant Infection Prevention

Study ID

NCT07195032

Start date

Sep 11, 2025

Status verified date

Sep, 2025

Completion date

Sep 11, 2027

Anticipated

Primary completion date

Sep 11, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Received a heart transplant
  • At least 1 year after transplant
  • At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
  • At least 1 year from anti-thymocyte globulin
  • At least 6 months after pulse dose steroid treatment or basiliximab treatment
  • No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
  • Clinically well

Exclusion Criteria:

  • History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
  • History of anaphylactic reaction to MMR vaccination

Study Design

Enrollment

60 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Measles, Mumps, Rubella Vaccination

Patients receiving MMR vaccination due to no historical vaccine OR a seronegativity for measles

Interventions

Commercial measles, mumps, and rubella (MMR) vaccine

Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.

Primary outcome measure

  • Number of participants who experience adverse reactions to the measles, mumps, and rubella vaccination [ Time Frame: Between 0-240 days after vaccine administration ]
  • Number of participants with resultant initial seropositivity against measles after vaccination [ Time Frame: Between 60-240 days after vaccine administration. ]

Central Contacts and Locations

Locations

Children's Mercy Hospital

Recruiting

Kansas City, Missouri, United States, 64108

Contacts

Victoria Blazek, PharmD, BCPPS

816-302-3724vmblazek@cmh.edu

More Information

Sponsor

Children's Mercy Hospital Kansas City

Last update posted

Sep 26, 2025

Last verified

Sep, 2025

Keywords

  • Measles
  • Mumps
  • Rubella
  • Live vaccine
  • Heart transplant

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Children's Mercy Hospital Kansas City on 2025-09-26.